Publication:
Neoadjuvant hormonal therapy in breast cancer

Placeholder

Departments

Organizational Unit

School / College / Institute

Organizational Unit
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU Authors

Co-Authors

Selcukbiricik, Fatih

Publication Date

Language

Embargo Status

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

The various types of ER-positive and HER-2-negative breast cancers have different treatment modalities. There are two options for the treatment of locally advanced breast cancer: chemotherapy or hormonal therapy. Chemotherapy can be particularly toxic for elderly postmenopausal patients, and neoadjuvant hormonal therapy (NHT) is an alternative for patients with hormone receptor-positive, locally advanced, postmenopausal breast cancer. This treatment is also highly beneficial for patients with comorbidities and can comprise tamoxifen and steroidal or nonsteroidal aromatase inhibitors (AIs). The best activities in clinical trials are observed with AIs. NHT produces good response rates (RRs) as well as adequate downstaging of tumor size such that breast-conserving surgery (BCS) may become an option. The optimal duration of such treatments should not be less than 4 months and may be continued for as long as 8 months.

Source

Publisher

Springer

Subject

Oncology

Citation

Has Part

Source

Breast Disease: Management and Therapies

Book Series Title

Edition

DOI

10.1007/978-3-319-26012-9_14

item.page.datauri

Link

Rights

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details